Wealthstreet Investment Advisors LLC Acquires New Holdings in Eli Lilly and Co (LLY)
Wealthstreet Investment Advisors LLC acquired a new position in Eli Lilly and Co (NYSE:LLY) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 36,850 shares of the company’s stock, valued at approximately $3,112,000.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Pathstone Family Office LLC increased its holdings in shares of Eli Lilly and by 100.0% during the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock valued at $4,774,000 after acquiring an additional 29 shares in the last quarter. Vantage Financial Partners Ltd. Inc. bought a new position in shares of Eli Lilly and during the second quarter valued at $494,000. Gradient Investments LLC bought a new position in shares of Eli Lilly and during the fourth quarter valued at $103,000. Acrospire Investment Management LLC increased its holdings in shares of Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares in the last quarter. Finally, MPS Loria Financial Planners LLC bought a new position in shares of Eli Lilly and during the second quarter valued at $128,000. Institutional investors and hedge funds own 76.20% of the company’s stock.
Several equities analysts have recently weighed in on the company. BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, December 5th. Credit Suisse Group reiterated a “hold” rating and issued a $80.00 price objective on shares of Eli Lilly and in a report on Friday, February 2nd. Leerink Swann lifted their price objective on Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $85.52 to $115.00 in a report on Friday, January 5th. Finally, Jefferies Group set a $100.00 price objective on Eli Lilly and and gave the stock a “buy” rating in a report on Tuesday, January 16th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $92.02.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.06. The business had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $5.93 billion. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period last year, the firm posted $0.95 earnings per share. equities analysts anticipate that Eli Lilly and Co will post 4.88 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be given a $0.5625 dividend. This represents a $2.25 annualized dividend and a yield of 2.95%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently -1,040.00%.
In other Eli Lilly and news, SVP Susan Mahony sold 36,585 shares of the firm’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $86.18, for a total value of $3,152,895.30. Following the transaction, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at $4,729,989.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $81.09, for a total value of $72,981.00. Following the completion of the transaction, the insider now directly owns 4,130 shares in the company, valued at $334,901.70. The disclosure for this sale can be found here. Insiders sold 259,610 shares of company stock worth $22,727,406 over the last three months. Insiders own 0.20% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.